CONSISTENT CLEARANCE

CONSISTENT
CLEARANCE ACROSS 3
REAL-WORLD STUDIES1-3

ILUMYA® (tildrakizumab-asmn)
demonstrated durable PASI
improvement at multiple time
points1-3

CONSISTENT CLEARANCE ACROSS 3
REAL-WORLD STUDIES1-3

ILUMYA® (tildrakizumab-asmn) demonstrated durable PASI improvement at
multiple time points1-3

ILUMYA® (tildrakizumab-asmn) Real-World Evidence
Median PASI in ILUMYA® (tildrakizumab-asmn) Across 3 Real-World Studies Median PASI in ILUMYA® (tildrakizumab-asmn) Across 3 Real-World Studies STUDY 1N=301Mean PASI: 15.8Mean PASI: 1.5Mean PASI: 1.8Mean PASI: 0.6Median PASI: 0.3STUDY 2n=25 (W4), n=24 (W12), n=23 (W24)2Mean PASI: 12.5STUDY 3N=1773Median PASI: 13.8WEEK 0WEEK 12WEEK 24YEAR 191%CLEARER95%CLEARER98%CLEARER86%CLEARER
Chart 1STUDY 1N=301STUDY 3N=1773Mean PASI: 15.8Mean PASI: 1.591%CLEARERMean PASI: 0.695%CLEARERMedian PASI: 0.398%CLEARERMean PASI: 1.886%CLEARERSTUDY 2n=25 (W4), n=24 (W12), n=23 (W24)2Mean PASI: 12.5Median PASI: 13.8WEEK 0WEEK 12WEEK 24YEAR 1

REAL-WORLD STUDY 1 was a post hoc, retrospective, observational study of patients ≥18 years of age with moderate-to-severe plaque psoriasis and treated with ILUMYA® 100 mg for at least 2 years; N=30.1

REAL-WORLD STUDY 2 was a 24-week, single-clinic study of ILUMYA® 100 mg in adult patients with moderate-to-severe plaque psoriasis who were eligible for systemic therapy. Data summarized by descriptive analysis; n=25 (Week 4); n=24 (Week 12); n=23 (Week 24).2

REAL-WORLD STUDY 3 was the 24-week, open-label Phase 4 TRIBUTE study of ILUMYA® 100 mg in adult patients with moderate-to-severe plaque psoriasis who were eligible for systemic biologic treatment. Analysis based on observed cases; N=177.3

5 YEARS OF LASTING CLEARANCE

ILUMYA® minimized measurable disease throughout the 5-year extension
studies of reSURFACE 1 and 24,5
EXPLORE 5-YEAR CLINICAL TRIAL DATA

5 YEARS OF LASTING
CLEARANCE

ILUMYA® minimized measurable disease throughout
the 5-year extension studies of reSURFACE 1 and 24,5
EXPLORE 5-YEAR CLINICAL TRIAL

Chart of Percentage of ILUMYA® (tildrakizumab-asmn) Patients Who Achieved PASI Chart of Percentage of ILUMYA® (tildrakizumab-asmn) Patients Who Achieved PASI P a tie n ts, % Baseline W ee k 4 W ee k 12 2 4 71 6 7 P A SI 90 P A SI 100 91% A chi e v ed P A SI 90 87% A chi e v ed P A SI 100 100 90 80 70 60 50 40 30 20 10 0 W ee k 2 4

Complete clearance was achieved by 87% of patients after 3 doses in REAL-WORLD STUDY 22

REAL-WORLD STUDY 2 was a 24-week, single-clinic study of ILUMYA® 100 mg in adult patients with moderate-to-severe plaque psoriasis who were eligible for systemic therapy. Data summarized by descriptive analysis; n=25 (Week 4); n=24 (Week 12); n=23 (Week 24).2
PASI=Psoriasis Area and Severity Index.

SCALP PSORIASIS REDUCTION

7X more ILUMYA® patients met the primary endpoint compared with placebo in a Phase 3 study4,6
SEE SCALP RESPONSE

INDICATION AND IMPORTANT SAFETY INFORMATION

ILUMYA® (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

CONTRAINDICATIONS

ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity

Cases of angioedema and urticaria occurred in ILUMYA-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy.

Infections

ILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.
Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA until the infection resolves.

Pretreatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA should be monitored closely for signs and symptoms of active TB during and after treatment.

Immunizations

Prior to initiating therapy with ILUMYA, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA should not receive live vaccines.

Adverse Reactions

The most common (≥1%) adverse reactions associated with ILUMYA treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea.

Please see full Prescribing Information.
 

References: 1. Data on File. Sun Pharmaceutical Industries, Inc. 2. ILUMYA® [package insert]. Princeton, NJ: Sun Pharmaceutical Industries, Inc. 3. Thaçi D, Piaserico S, Warren RB, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol. 2021;185(2):323-334. 4. Lebwohl MG, Leonardi CL, Mehta NN, et al. Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). J Am Acad Dermatol. 2021;84(2):398-407. 5.Wei NW, Chi S, Lebwohl MG. Retrospective analysis in patients with moderate to severe plaque psoriasis treated with tildrakizumab: real-life clinical data. J Psoriasis Psoriatic Arthritis. 2022;7(2):55-59.